Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features
Pharmaceutics · 26.01.2024 · 16 (2) · 178
DOI: 10.3390/pharmaceutics16020178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.01.2024. Verfasst von Christi A Wilkins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), Faculty of Health Sciences, North-West University, Private Bag X6001, Potchefstroom 25…. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation, National Research Foundation of South Africa.
Abstract (Originalsprache)
Whilst monotherapy is traditionally the preferred treatment starting point for chronic conditions such as hypertension and diabetes, other diseases require the use of multiple drugs (polytherapy) from the onset of treatment (e.g., human immunodeficiency virus acquired immunodeficiency syndrome, tuberculosis, and malaria). Successful treatment of these chronic conditions is sometimes hampered by patient non-adherence to polytherapy. The options available for polytherapy are either the sequential addition of individual drug products to deliver an effective multi-drug regimen or the use of a single fixed-dose combination (FDC) therapy product. This article intends to critically review the use of FDC drug therapy and provide an insight into FDC products which are already commercially available. Shortcomings of FDC formulations are discussed from multiple perspectives and research gaps are identified. Moreover, an overview of fundamental formulation considerations is provided to aid formulation scientists in the design and development of new FDC products.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), Faculty of Health Sciences, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa.
ORCID-Profile: Hannlie Hamman, Josias H Hamman
Förderung
- National Research Foundation
- National Research Foundation of South Africa
Zitieren
APA
Wilkins, C. A., Hamman, H., Hamman, J. H., & Steenekamp, J. H. (2024). Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features. Pharmaceutics, 16(2), 178. https://doi.org/10.3390/pharmaceutics16020178
Vancouver
Wilkins CA, Hamman H, Hamman JH, Steenekamp JH. Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features. Pharmaceutics. 2024;16(2):178. doi:10.3390/pharmaceutics16020178
BibTeX
@article{Wilkins2024,
author = {Wilkins, Christi A and Hamman, Hannlie and Hamman, Josias H and Steenekamp, Jan H},
title = {Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {2},
pages = {178},
doi = {10.3390/pharmaceutics16020178}
}
EUVIMED